Format

Send to

Choose Destination
Am J Respir Crit Care Med. 2009 May 15;179(10):950-4. doi: 10.1164/rccm.200807-1125OC. Epub 2009 Feb 6.

Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.

Author information

1
INSERM Unit 774, Institut Pasteur of Lille, Lille, France.

Abstract

RATIONALE:

Previous data suggested that serum levels of soluble mesothelin (SM) are related to tumor size and may have prognostic significance in malignant pleural mesothelioma (MPM).

OBJECTIVES:

We tested the hypothesis that this marker could also be useful for monitoring response to treatment.

METHODS:

Serial measurements of SM were determined in 40 patients diagnosed with MPM and subjected to gene-transfer therapy using intrapleural infusion of an adenoviral vector expressing human IFN-beta or conventional treatment (mainly chemotherapy).

MEASUREMENTS AND MAIN RESULTS:

In patients with baseline SM levels greater than 1 nM/L and disease progression after therapy, SM levels increased by 2.1 nM/L at two, 5.2 nM/L at four and 1.3 nM/L at 6 months. Patients with initial SM below 1 nM/L had a similar but more moderate increase of SM over time. Patients who responded to treatment or were considered stable had an initial small decrease of SM followed by a return to baseline values after 6 months of follow-up. In patients with baseline SM levels greater than 1 nM/L, increasing levels were associated with a significantly shorter median survival than in patients with stable or decreasing SM levels (4.4 vs. 27.7 months; P = 0.012).

CONCLUSIONS:

Increasing serum levels of SM were associated with disease progression and worse outcome, whereas stable or decreasing values suggested response to treatment. If confirmed in larger series, SM could be used to monitor patients with malignant pleural mesothelioma under treatment.

PMID:
19201924
DOI:
10.1164/rccm.200807-1125OC
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center